Oruka Therapeutics, Inc. ORKA Less than 12 months
Less than 12 months at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months.
The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s less than 12 months.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s less than 12 months?
- Oruka Therapeutics, Inc. (ORKA) reported less than 12 months of $348.72M in Q1 2026.
- How has Oruka Therapeutics, Inc.'s less than 12 months changed year-over-year?
- Oruka Therapeutics, Inc.'s less than 12 months increased by 58.6% year-over-year, from $219.8M to $348.72M.